GBIO — Generation Bio Co Share Price
0.000.00%
Last trade - 00:00- $22.99m
- -$134.57m
- $19.89m
- 29
- 66
- 38
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.31 | ||
| Price to Tang. Book | 0.31 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.77% | ||
| Return on Equity | -70.06% | ||
| Operating Margin | -331.33% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 5.9 | 19.89 | 14.94 | 4.02 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Generation Bio Co. is a biotechnology company. The Company is engaged in developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. It focuses on autoimmune targets that have been undruggable or poorly drugged selectively in T cells. Its proprietary cell-targeted lipid nanoparticle (ctLNP) technology enables selective access to T cells and precise target inhibition by siRNA to selectively modulate T cells, blocking autoimmune tissue damage while sparing the broader immune system. Its proprietary stealth technology prevents its LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen to less than 1%, enabling potency and selectivity. Its selective delivery allows it to inhibit targets in T cells while sparing critical function in other cell types.
Directors
- Jason Rhodes NEC (52)
- Cameron Mcdonough PRE (50)
- Matthew Norkunas CFO (43)
- Antoinette Paone COO (44)
- Matthew Stanton CSO (48)
- Douglas Kerr OTH (54)
- Tracy Zimmermann OTH (51)
- Ron Cooper DRC (58)
- Gustav Christensen IND (73)
- Jeffrey Jonas IND (68)
- Donald Nicholson IND
- Anthony Quinn IND (59)
- Charles Rowland IND (62)
- Catherine Stehman-Breen IND (58)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- October 21st, 2016
- Public Since
- June 12th, 2020
- No. of Shareholders
- 70
- No. of Employees
- 115
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 67,035,236
- Address
- 301 BINNEY STREET, CAMBRIDGE, 02142
- Web
- https://generationbio.com/
- Phone
- +1 8575295908
- Auditors
- Ernst & Young LLP
Upcoming Events for GBIO
Q3 2025 Generation Bio Co Earnings Release
Similar to GBIO
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Generation Bio Co share price?
As of Today at 20:47 UTC, shares in Generation Bio Co are trading at $0.34. This share price information is delayed by 15 minutes.
How has the Generation Bio Co share price performed this year?
Shares in Generation Bio Co last closed at $0.34 and the price had moved by -85.94% over the past 365 days. In terms of relative price strength the Generation Bio Co share price has underperformed the S&P500 Index by -87.43% over the past year.
What are the analyst and broker recommendations for Generation Bio Co?
The overall consensus recommendation for Generation Bio Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Generation Bio Co dividend yield?
Generation Bio Co does not currently pay a dividend.
Does Generation Bio Co pay a dividend?
Generation Bio Co does not currently pay a dividend.
When does Generation Bio Co next pay dividends?
Generation Bio Co does not currently pay a dividend.
How do I buy Generation Bio Co shares?
To buy shares in Generation Bio Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Generation Bio Co?
As of the previous close price of $0.34, shares in Generation Bio Co had a market capitalisation of $22.99m.
Where are Generation Bio Co shares listed?
Here are the trading details for Generation Bio Co:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: GBIO
What kind of share is Generation Bio Co?
Based on an overall assessment of its quality, value and momentum Generation Bio Co is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Generation Bio Co share price forecast for 2025?
The analyst consensus target price for shares in Generation Bio Co is $6.50. That is 1795.04% above the last closing price of $0.34.
Analysts covering Generation Bio Co currently have a consensus Earnings Per Share (EPS) forecast of -$1.10 for the next financial year.
Find out moreWhat is the trend in the Generation Bio Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Generation Bio Co. Over the past six months, its share price has underperformed the S&P500 Index by -71.38%.
As of the last closing price of $0.34, shares in Generation Bio Co were trading -67.29% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Generation Bio Co PE Ratio?
The Generation Bio Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Generation Bio Co?
Generation Bio Co's management team is headed by:
- Jason Rhodes - NEC
- Cameron Mcdonough - PRE
- Matthew Norkunas - CFO
- Antoinette Paone - COO
- Matthew Stanton - CSO
- Douglas Kerr - OTH
- Tracy Zimmermann - OTH
- Ron Cooper - DRC
- Gustav Christensen - IND
- Jeffrey Jonas - IND
- Donald Nicholson - IND
- Anthony Quinn - IND
- Charles Rowland - IND
- Catherine Stehman-Breen - IND